In addition, detectable phosphorylation of FLT3wt, but not FLT3-ITD, has been observed using the plasma inhibitory activity assay with human plasma samples from patients administered quizartinib [28], suggesting that the efficacy of quizartinib may also be attenuated in the presence of FL in AML patients. Here, FLT3 is linked to acute myeloid leukemia.